Genetically Modified Mammalian Cells for Viral Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine production methods for viral infections, such as influenza, are labor-intensive, expensive, and prone to variability due to reliance on traditional egg-based methods, leading to adverse reactions and inefficiencies in producing viral precursor proteins.
Innovation Solution
Genetically modified cells with disrupted genes, such as those listed in Tables 1a or 1b, are used to increase viral replication when infected, allowing for more efficient virus production and vaccine development, including the use of siRNA to inhibit gene expression and enhance viral replication in cell cultures or fertilized eggs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional egg-based methods are used for vaccine production, then viral replication can be achieved, but the process becomes labor-intensive, expensive, and prone to variability
Solution Approach 1:
The invention extracts and eliminates the problematic egg-based production system, replacing it with cultured mammalian cells that have been genetically modified to overexpress viral precursor proteins. This extraction of the virus from its traditional egg-based production environment resolves the technical contradiction by removing the labor-intensive and variable egg-based process while maintaining viral replication capability in a more controlled cell culture system.
Solution Approach 2:
The invention changes the biological parameters of the production system by introducing genetically modified mammalian cells that overexpress viral precursor proteins through recombinant DNA technology. This parameter change in gene expression levels and cell type transforms the production system from traditional egg-based methods to a more efficient cell culture-based system, improving productivity while reducing process complexity.
2Quantity of substance
If recombinant DNA methods are used to produce viral vaccine proteins in insect or mammalian cells, then vaccine production is achieved, but the cost per milligram protein is higher than cell culture and egg production methods
Solution Approach 1:
The invention creates a universal production system using mammalian cells that can produce multiple viral precursor proteins simultaneously through co-expression of multiple recombinant genes. This multi-functional approach allows the same cell culture system to generate various viral proteins (such as HA, NA, and other influenza proteins) in a single production run, improving quantity while maintaining cost-effectiveness through system consolidation.
Solution Approach 2:
The invention employs composite biological systems by combining mammalian cells with recombinant viral gene sequences to create hybrid production cells that express viral proteins. This composite approach integrates the advantages of mammalian cell culture (scalability, protein folding capability) with the specificity of recombinant DNA technology, achieving high protein yield at reduced cost compared to traditional insect or mammalian cell recombinant methods.
3Reliability
If traditional vaccine production methods are used, then vaccines can be produced, but adverse reactions occur due to impurities or biologic properties of vaccine proteins
Solution Approach 1:
The invention converts the traditional approach of using whole virus or virus-like particles in eggs (which generate impurities) into a system that produces purified viral precursor proteins. By expressing only the specific viral proteins of interest in genetically modified mammalian cells, the process eliminates unwanted egg proteins and cellular impurities, transforming the harmful impurity problem into a benefit of highly purified vaccine antigens.
Solution Approach 2:
The invention segments the viral structure by producing individual viral precursor proteins (such as hemagglutinin and neuraminidase) separately through recombinant expression, rather than producing whole viruses. This segmentation allows for purified protein production without the contamination of viral genomes, lipids, or other components that could cause adverse reactions, while maintaining the immunogenicity of the key viral antigens.
Data Source
AI summary
The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.